Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
Last trade$1.18
Day change+$0.2348 (+24.97%)
Day range$0.90 – $1.29
Volume3,681,135
Market cap$42M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$41.85M
Price / earnings
—
Price / book
4.12×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.73×
Profitability
Earnings per share
-$0.40
Return on assets
-135.9%
Return on equity
-177.15%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.03×
Current ratio
5.36×
Quick ratio
5.36×
Cash ratio
4.94×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$17.07M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GANX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.78M
$2.54M
$2.59M
$2.12M
$1.94M
$2.33M
$2.11M
$2.11M
Research and development
$1.42M
$2.14M
$2.76M
$2.35M
$2.85M
$2.76M
$2.26M
$1.22M
Total operating expenses
$3.2M
$4.68M
$5.35M
$4.47M
$4.79M
$5.09M
$4.37M
$3.33M
Operating income
-$3.2M
-$4.68M
-$5.35M
-$4.47M
-$4.79M
-$5.09M
-$4.37M
-$3.33M
Interest expense
$41.96K
$0
$0
$0
$78.07K
$0
$0
$0
Income before taxes
-$3.09M
-$4.57M
-$5.43M
-$4.47M
-$4.74M
-$5.67M
-$4.43M
-$3.26M
Income taxes
$72.49K
$104.07K
$183.07K
$70.12K
$549.29K
$141.21K
$100.51K
$504.74K
Net income
-$3.16M
-$4.68M
-$5.61M
-$4.54M
-$5.28M
-$5.81M
-$4.53M
-$3.77M
Net income attributable to common shareholders
-$3.16M
-$4.68M
-$5.61M
-$4.54M
-$5.28M
-$5.81M
-$4.53M
-$3.77M
EBITDA
-$3.18M
-$4.65M
-$5.33M
-$4.44M
-$4.76M
-$5.07M
-$4.35M
-$3.31M
Basic earnings per share
-$0.07
-$0.11
-$0.13
-$0.12
-$0.15
-$0.19
-$0.16
-$0.14
Diluted earnings per share
-$0.07
-$0.11
-$0.13
-$0.12
-$0.15
-$0.19
-$0.16
-$0.14
Recent news
Company coverage with links to the original publishers.
Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #2 (Buy) rating due to rising earnings estimates. The company's consensus estimate for fiscal year 2026 is -$0.43 per share with no year-over-year change, but analysts have increased their estimates by 17.3% over the past three months. The upgrade positions GANX in the top 20% of Zacks-covered stocks, suggesting potential near-term stock price appreciation.
Gain Therapeutics announced a poster presentation of long-term open-label data on its lead drug candidate rexaceract (GT-02287), a GCase modulator for Parkinson's disease treatment, at the International Congress of Parkinson's Disease and Movement Disorders in Seoul, Korea on October 7, 2026. The presentation will showcase clinical trial results from the ongoing Phase 1b study evaluating safety and tolerability in people with PD with or without GBA1 mutations.
Gain Therapeutics announced that CEO Gene Mack will participate in one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference (September 14-16, 2026) in New York City. The company will provide an on-demand presentation on September 11, 2026. Gain is a clinical-stage biotech company developing allosteric small molecule therapies, with its lead candidate rexaceract currently in Phase 1b trials for Parkinson's disease treatment.
Gain Therapeutics announced that President and CEO Gene Mack will participate in a virtual fireside chat and one-on-one meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on June 15-16, 2026. The clinical-stage biotech company is advancing its lead candidate GT-02287 for Parkinson's disease treatment in a Phase 1b clinical trial.
Gain Therapeutics announced that CEO Gene Mack will participate in a fireside chat at the 38th Annual ROTH Conference on March 23, 2026. The company will also present additional clinical and biomarker data from its Phase 1b study of GT-02287 for Parkinson's disease at AD/PD 2026, including interim analysis results. The company remains on track to initiate Phase 2 clinical trials.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.